Emman Shubbar

827 total citations
25 papers, 608 citations indexed

About

Emman Shubbar is a scholar working on Oncology, Molecular Biology and Epidemiology. According to data from OpenAlex, Emman Shubbar has authored 25 papers receiving a total of 608 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 9 papers in Molecular Biology and 9 papers in Epidemiology. Recurrent topics in Emman Shubbar's work include Neuroendocrine Tumor Research Advances (8 papers), Neuroblastoma Research and Treatments (8 papers) and Lung Cancer Research Studies (6 papers). Emman Shubbar is often cited by papers focused on Neuroendocrine Tumor Research Advances (8 papers), Neuroblastoma Research and Treatments (8 papers) and Lung Cancer Research Studies (6 papers). Emman Shubbar collaborates with scholars based in Sweden, United States and Netherlands. Emman Shubbar's co-authors include Charlotta Enerbäck, Khalil Helou, Anikó Kovács, Zakaria Einbeigi, Szilárd Nemes, Shahin Hajizadeh, Toshima Z. Parris, Per Karlsson, K. Gunnarsdóttir and Karen S. Anderson and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Scientific Reports.

In The Last Decade

Emman Shubbar

23 papers receiving 601 citations

Peers

Emman Shubbar

ONCOL

PRM

IMMUN

Tsion Z. Minas United States

Oleg I. Kit Russia

Ding Yang China

Lada Krilov United States

Xiaofeng Li China

Lihua Huang China

Silvio Ken Garattini Italy

Ming‐Shen Dai Taiwan

Anbok Lee South Korea

Tsion Z. Minas United States

Emman Shubbar

310 ×1.0

200 ×1.2

ONCOL

125 ×1.0

128 ×1.2

PRM

58 ×0.6

IMMUN

Citations per year, relative to Emman Shubbar Emman Shubbar (= 1×) peers Tsion Z. Minas

Countries citing papers authored by Emman Shubbar

Since Specialization

Citations

This map shows the geographic impact of Emman Shubbar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emman Shubbar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emman Shubbar more than expected).

Fields of papers citing papers by Emman Shubbar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emman Shubbar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emman Shubbar. The network helps show where Emman Shubbar may publish in the future.

Co-authorship network of co-authors of Emman Shubbar

This figure shows the co-authorship network connecting the top 25 collaborators of Emman Shubbar. A scholar is included among the top collaborators of Emman Shubbar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emman Shubbar. Emman Shubbar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shubbar, Emman, Toshima Z. Parris, Britta Langen, et al.. (2024). Effects of Recombinant α1-Microglobulin on Early Proteomic Response in Risk Organs after Exposure to 177Lu-Octreotate. International Journal of Molecular Sciences. 25(13). 7480–7480.

Andersson, Charlotte, Amin Al-Awar, Emman Shubbar, et al.. (2023). Co-administration with A1M does not influence apoptotic response of 177Lu-octreotate in GOT1 neuroendocrine tumors. Scientific Reports. 13(1). 6417–6417. 1 indexed citations

Spetz, Johan, et al.. (2021). Neuroblastoma xenograft models demonstrate the therapeutic potential of 177Lu-octreotate. BMC Cancer. 21(1). 950–950. 6 indexed citations

Spetz, Johan, et al.. (2020). Increased therapeutic effect on medullary thyroid cancer using a combination of radiation and tyrosine kinase inhibitors. PLoS ONE. 15(5). e0233720–e0233720. 2 indexed citations

Larsson, Malin, Nils-Petter Rudqvist, Johan Spetz, et al.. (2020). Long-term transcriptomic and proteomic effects in Sprague Dawley rat thyroid and plasma after internal low dose 131I exposure. PLoS ONE. 15(12). e0244098–e0244098. 11 indexed citations

Spetz, Johan, Britta Langen, Nils-Petter Rudqvist, et al.. (2019). Transcriptional effects of 177Lu-octreotate therapy using a priming treatment schedule on GOT1 tumor in nude mice. EJNMMI Research. 9(1). 28–28. 4 indexed citations

Andersson, Charlotte, Emman Shubbar, Emil Schüler, et al.. (2019). Recombinant α₁-Microglobulin Is a Potential Kidney Protector in ¹⁷⁷Lu-Octreotate Treatment of Neuroendocrine Tumors. Journal of Nuclear Medicine. 60(11). 1600–1604. 12 indexed citations

Spetz, Johan, et al.. (2019). Gemcitabine potentiates the anti-tumour effect of radiation on medullary thyroid cancer. PLoS ONE. 14(11). e0225260–e0225260. 7 indexed citations

Arvidsson, Yvonne, Emman Shubbar, Viktor Johanson, et al.. (2019). 177Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition. Endocrine Related Cancer. 26(4). 437–449. 18 indexed citations

10.

Shubbar, Emman, et al.. (2018). Adenine-Induced Chronic Renal Failure in Rats: A Model of Chronic Renocardiac Syndrome with Left Ventricular Diastolic Dysfunction but Preserved Ejection Fraction. Kidney & Blood Pressure Research. 43(4). 1053–1064. 16 indexed citations

11.

Hammarsten, Ola, et al.. (2016). High-NaCl Diet Aggravates Cardiac Injury in Rats with Adenine-Induced Chronic Renal Failure and Increases Serum Troponin T Levels. Cardiorenal Medicine. 6(4). 317–327. 4 indexed citations

12.

Loseva, Olga, Emman Shubbar, Siamak Haghdoost, et al.. (2014). Chronic Low Dose Rate Ionizing Radiation Exposure Induces Premature Senescence in Human Fibroblasts that Correlates with Up Regulation of Proteins Involved in Protection against Oxidative Stress. Proteomes. 2(3). 341–362. 24 indexed citations

13.

Shubbar, Emman, Anikó Kovács, Shahin Hajizadeh, et al.. (2013). Elevated cyclin B2 expression in invasive breast carcinoma is associated with unfavorable clinical outcome. BMC Cancer. 13(1). 1–1. 277 indexed citations

14.

Shubbar, Emman, Khalil Helou, Anikó Kovács, et al.. (2013). High levels of γ-glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer. BMC Cancer. 13(1). 47–47. 36 indexed citations

15.

Shubbar, Emman. (2012). ANALYSIS OF NOVEL BIOMARKERS FOR UNFAVORABLE BREAST CANCER PROGNOSIS. Gothenburg University Publications Electronic Archive (Gothenburg University). 1 indexed citations

16.

Shubbar, Emman, et al.. (2011). Psoriasin (S100A7) increases the expression of ROS and VEGF and acts through RAGE to promote endothelial cell proliferation. Breast Cancer Research and Treatment. 134(1). 71–80. 64 indexed citations

17.

Anderson, Karen S., et al.. (2010). Elevation of serum epidermal growth factor and interleukin 1 receptor antagonist in active psoriasis vulgaris. British Journal of Dermatology. 163(5). 1085–1089. 54 indexed citations

18.

Shubbar, Emman, et al.. (2009). Expression patterns of S100 proteins in melanocytes and melanocytic lesions. Melanoma Research. 19(4). 215–225. 31 indexed citations

19.

Öfverholm, Anna, Eva Lagberg Arkblad, Stanko Skrtic, et al.. (2009). Two cases of 5-fluorouracil toxicity linked with gene variants in the DPYD gene. Clinical Biochemistry. 43(3). 331–334. 20 indexed citations

20.

Enerbäck, Charlotta, et al.. (2008). Expression of S100 proteins in the progression of melanocytic lesions. European Journal of Cancer Supplements. 6(9). 133–133. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact